- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00331643
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors
Study Overview
Status
Conditions
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Alveolar Childhood Rhabdomyosarcoma
- Embryonal Childhood Rhabdomyosarcoma
- Childhood Synovial Sarcoma
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the response rate to ixabepilone in various strata of recurrent solid malignant tumors of childhood and young adulthood, including all of the following: Embryonal or alveolar rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma/peripheral neuroectodermal tumor, synovial sarcoma or malignant peripheral nerve sheath tumor, Wilms' tumor, and neuroblastoma.
II. Determine the time to progression for each tumor stratum. III. Prospectively evaluate the feasibility and utility of automated volumetric tumor measurement in patients with measurable pulmonary metastases, and descriptively compare volumetric measurements to 1-dimensional (RECIST criteria) and 2-dimensional (WHO criteria) measurements.
IV. Define and describe the toxicities of ixabepilone.
OUTLINE: This is a multicenter study. Patients are stratified according to disease (Ewing's sarcoma/ peripheral neuroectodermal tumor vs osteosarcoma vs alveolar or embryonal rhabdomyosarcoma vs Wilms' tumor vs neuroblastoma vs synovial sarcoma/malignant peripheral nerve sheath tumor).
Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed up every year for 5 years.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Arcadia, California, United States, 91006-3776
- Children's Oncology Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed diagnosis (at original diagnosis or recurrence) of 1 of the following:
- Embryonal or alveolar rhabdomyosarcoma
- Osteosarcoma*
- Ewing's sarcoma /peripheral neuroectodermal tumor*
- Synovial sarcoma or malignant peripheral nerve sheath tumor*
Wilms' tumor*
- Age ≤ 21 years at original diagnosis
Neuroblastoma
- Age ≤ 21 years at original diagnosis
Clinically or radiographically measurable or evaluable (by iodine I 123 metaiodobenzoguanine sulfate [^123I-MIBG] or bone scan [evaluable tumors must be positive at ≥ 1 site])
- If lesion was previously irradiated, a biopsy must be performed ≥ 6 weeks after completion of radiotherapy and viable neuroblastoma must be demonstrated
- No elevated urinary catecholamines and/or bone marrow evidence of tumor with measurable disease clinically or by imaging modalities (CT scan, MRI, ^123I-MIBG, or bone scan)
- Refractory or recurrent disease with no known curative treatment options
- ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100% (patients > 16 years of age) OR Lansky PS 50-100% (patients ≤ 16 years)
- Life expectancy ≥ 8 weeks
- No evidence of active graft-versus-host disease
- Absolute neutrophil count ≥ 1,500/mm³ (no growth factors)
- Platelet count ≥ 75,000/mm³ (transfusion independent)
- Not pregnant or nursing
- Fertile patients must agree to use effective contraception
- Negative pregnancy test
- Hemoglobin ≥ 8 g/dL (may receive RBC transfusions)
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT ≤ 2.5 times ULN
No clinically significant unrelated systemic illness that would preclude study treatment, including any of the following:
- Serious infections
- Hepatic, renal, or other organ dysfunction
- CNS toxicity ≤ grade 2
- No pre-existing sensory or motor neuropathy ≥ grade 2
- Seizure disorder allowed provided it is well controlled by anticonvulsants
- No known prior severe hypersensitivity reaction to agents containing Cremophor EL®
- Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
- More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks if prior nitrosourea)
- At least 7 days since prior biologic agents
- At least 2 weeks since prior local palliative (small-port) radiotherapy
- At least 6 months since prior craniospinal radiotherapy OR radiotherapy to ≥ 50% of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- At least 4 months since prior allogeneic stem cell transplant (SCT)
- At least 2 months since prior autologous SCT
- No prior taxane (paclitaxel, docetaxel) therapy
- More than 1 week since prior growth factor use (except epoetin alfa)
More than 1 week since prior and no concurrent strong inhibitors ofCYP3A4, including any of the following:
- Clarithromycin
- Troleandomycin
- Erythromycin
- Ketoconazole
- Itraconazole
- Fluconazole (doses > 3mg/kg/day)
- Voriconazole
- Nefazodone
- Fluvoxamine
- Verapamil
- Diltiazem
- Amiodarone
- Grapefruit juice
More than 1 week since prior and no concurrent enzyme-inducing anticonvulsants, including any of the following:
- Carbamazepine
- Felbamate
- Phenobarbital
- Phenytoin
- Primidone
- Oxcarbazepine
- No concurrent aprepitant
- No concurrent Hypericum perforatum (St. John's wort)
- No concurrent sargramostim (GM-CSF) or interleukin-11
- No other concurrent chemotherapy or immunomodulating agents
- No concurrent radiotherapy
- Concurrent steroids allowed for pain or chemotherapy-associated nausea or vomiting
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (ixabepilone)
Patients receive ixabepilone IV over 1 hour on days 1-5.
Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to progression
Time Frame: From enrollment until disease progression, death because of treatment complications, resection of measurable tumor or last patient follow-up whichever is first, assessed up to 5 years
|
Estimated using the product-limit method of Kaplan and Meier.
|
From enrollment until disease progression, death because of treatment complications, resection of measurable tumor or last patient follow-up whichever is first, assessed up to 5 years
|
Progression-free survival (PFS)
Time Frame: At 6 months
|
The probability of PFS at 6 months will be summarized.
|
At 6 months
|
Response rate (complete response [CR] and partial response [PR]) according to Response Evaluation Criteria in Solid Tumor (RECIST) and World Health Organization (WHO) criteria
Time Frame: Up to 5 years
|
Response rates will be calculated as the percent of patients whose best response is a CR or PR, and the fraction of responses obtained will have a 95% confidence interval, which takes into consideration the two-stage nature of the design.
|
Up to 5 years
|
Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Time Frame: Up to 5 years
|
Toxicity information recorded will include the type, severity, time of onset, time of resolution, and the probable association with the study regimen.
Tables will be constructed to summarize the observed incidence by severity and type of toxicity.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brigitte Widemann, Children's Oncology Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Genetic Diseases, Inborn
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Neoplastic Syndromes, Hereditary
- Neoplasms, Complex and Mixed
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Myosarcoma
- Neoplasms
- Sarcoma
- Recurrence
- Sarcoma, Ewing
- Osteosarcoma
- Neuroblastoma
- Rhabdomyosarcoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Wilms Tumor
- Neuroectodermal Tumors, Primitive, Peripheral
- Rhabdomyosarcoma, Embryonal
- Sarcoma, Synovial
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Epothilones
- Epothilone B
Other Study ID Numbers
- NCI-2012-01826 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA098543 (U.S. NIH Grant/Contract)
- COG-ADVL0524
- CDR0000472912
- NCI-P6451
- NCI-06-C-0146
- ADVL0524 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Neuroblastoma
-
National Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Refractory NeuroblastomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 NeuroblastomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 NeuroblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S NeuroblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Unresectable Neuroblastoma | Regional NeuroblastomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable OsteosarcomaUnited States, Canada
Clinical Trials on ixabepilone
-
Weill Medical College of Cornell UniversityBristol-Myers SquibbCompletedMetastatic Breast CancerUnited States
-
R-PharmNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Cedars-Sinai Medical CenterBristol-Myers SquibbTerminatedUrogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, MaleUnited States
-
Eisai Inc.Completed
-
R-PharmCompletedSolid MalignanciesUnited States
-
R-PharmCompleted
-
R-PharmCompletedStomach NeoplasmsKorea, Republic of, Taiwan, Japan, Singapore, Hong Kong